-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $41

Benzinga·10/07/2026 14:30:41
Listen to the news
Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and raises the price target from $40 to $41.